D. Boral Capital Begins Coverage on Tevogen Bio (NASDAQ:TVGN)

Investment analysts at D. Boral Capital assumed coverage on shares of Tevogen Bio (NASDAQ:TVGN) in a note issued to investors on Tuesday, MarketBeat.com reports. The brokerage set a “buy” rating and a $10.00 price target on the stock.

Tevogen Bio Trading Down 6.3 %

Tevogen Bio stock opened at $1.19 on Tuesday. The business’s 50-day simple moving average is $1.35 and its 200 day simple moving average is $1.15. Tevogen Bio has a 12-month low of $0.26 and a 12-month high of $8.35.

Hedge Funds Weigh In On Tevogen Bio

Several hedge funds have recently added to or reduced their stakes in TVGN. HGC Investment Management Inc. acquired a new position in Tevogen Bio in the third quarter valued at about $82,000. China Universal Asset Management Co. Ltd. acquired a new stake in Tevogen Bio in the 4th quarter valued at approximately $38,000. JPMorgan Chase & Co. raised its position in Tevogen Bio by 74.2% in the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock valued at $40,000 after buying an additional 16,695 shares during the last quarter. Geode Capital Management LLC grew its stake in Tevogen Bio by 31.2% in the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company’s stock valued at $465,000 after purchasing an additional 107,566 shares in the last quarter. Finally, Barclays PLC grew its stake in Tevogen Bio by 39.2% in the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock valued at $48,000 after purchasing an additional 12,847 shares in the last quarter.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.